Intra-Cellular Therapies (ITCI) : 8 days before expiry, shorts in Intra-Cellular Therapies (ITCI) have reduced from 4,530,654 on Jul 29, 2016, to 4,462,245 on August 15, 2016. On an average, 552,292 shares are traded on the exchange. The outstanding bearish positions are equal to 14.1% of the float. Short sellers have covered -68,409 shares, a reduction of -1.5%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Intra-Cellular Therapies (NASDAQ:ITCI): The stock opened at $41.81 on Wednesday but the bulls could not build on the opening and the stock topped out at $42.83 for the day. The stock traded down to $40.14 during the day, due to lack of any buying support eventually closed down at $40.65 with a loss of -3.12% for the day. The stock had closed at $41.96 on the previous day. The total traded volume was 611,116 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Intra-Cellular Therapies, Inc., Riggs Rory B, had purchased 28,571 shares in a transaction dated on February 5, 2014. The transaction was executed at $17.5 per share with total amount equaling $499,993.
ITI Inc. is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc.